Korro Bio Deal Termination with Novo Nordisk A/S
Korro Bio received notice from Novo Nordisk of its election to terminate their 2024 research collaboration and license agreement for convenience, effective February 1, 2027. The partnership, which focused on cardiometabolic targets, had been paused since November 2025 and will now conclude with all licenses terminated and no milestone payments earned.
- Counterparty
- Novo Nordisk A/S
“Initiating dosing in ANCHOR brings KRRO-121 a meaningful step closer to these patients, and we look forward to dosing participants with UCDs in the first half of 2027. In AATD, our preclinical data showing over 95% correction of the disease-causing transcripts gives us confidence as we prepare KRRO-111 for the clinic. Both programs reflect what our OPERA platform is intended to do: correct disease at the level of RNA, with the precision to generate the protein of interest and convenience of subcutaneous administration. We are focused on execution, with two GalNAc-delivered RNA-editing programs advancing toward clinical data, and a cash runway into the second half of 2028.”
Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio